Last update 10 May 2025
Hefei Enrit Pharmaceutical Co., Ltd.

Hefei Enrit Pharmaceutical Co., Ltd.

Private Company | Subsidiary Company|2011|Anhui Sheng, China

Overview

Tags

Immune System Diseases
Nervous System Diseases
Otorhinolaryngologic Diseases
Small molecule drug

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Immune System Diseases2
Nervous System Diseases1
Infectious Diseases1
Top 5 Drug TypeCount
Small molecule drug2
Top 5 TargetCount
DHODH(Dihydroorotate dehydrogenase)1
H1 receptor(Histamine H1 receptor)1

Related

2
Drugs associated with Hefei Enrit Pharmaceutical Co., Ltd.
Teriflunomide
Target
DHODH
Mechanism
DHODH inhibitors
Active Org.
Sanofi-Aventis Recherche et Développement SA [+8]
Originator Org.
SanofiSanofi
Active Indication
Multiple Sclerosis, Relapsing-Remitting [+3]
Inactive Indication
Influenza, Human [+1]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
United States
First Approval Date12 Sep 2012
Desloratadine Citrate Disodium
Target
H1 receptor
Mechanism
H1 receptor antagonists
Active Org.
Hefei Enrit Pharmaceutical Co., Ltd.Hefei Enrit Pharmaceutical Co., Ltd. [+1]
Originator Org.
Hefei Enrit Pharmaceutical Co., Ltd.Hefei Enrit Pharmaceutical Co., Ltd.
Active Indication
Rhinitis, Allergic [+3]
Inactive Indication-
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
China
First Approval Date18 Feb 2009
22
Clinical Trials associated with Hefei Enrit Pharmaceutical Co., Ltd.
CTR20244677
/ RecruitingPhase 2
评价HY-021068 片在系统性硬化症患者中的有效性、安全性和暴露-效应关系的多中心、随机、双盲、安慰剂平行对照的II期临床试验
[Translation] A multicenter, randomized, double-blind, placebo-controlled phase II clinical trial to evaluate the efficacy, safety, and exposure-effect relationship of HY-021068 tablets in patients with systemic sclerosis
CTR20244039
/ RecruitingPhase 1
HY-078020片在健康志愿者中的单次给药耐受性及初步PK/PD研究
[Translation] Single-dose tolerability and preliminary PK/PD study of HY-078020 tablets in healthy volunteers
CTR20241711
/ CompletedPhase 2
一项评价枸地氯雷他定口服溶液在荨麻疹和过敏性鼻炎婴幼儿中的药代动力学和安全性研究
[Translation] A study to evaluate the pharmacokinetics and safety of desloratadine citrate oral solution in infants and young children with urticaria and allergic rhinitis
100 Clinical Results associated with Hefei Enrit Pharmaceutical Co., Ltd.
Login to view more data
0 Patents (Medical) associated with Hefei Enrit Pharmaceutical Co., Ltd.
Login to view more data
100 Deals associated with Hefei Enrit Pharmaceutical Co., Ltd.
Login to view more data
100 Translational Medicine associated with Hefei Enrit Pharmaceutical Co., Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 19 Jun 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Phase 1
1
1
Approved
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
Desloratadine Citrate Disodium
 ( H1 receptor )		Rhinitis, Allergic
More
Approved
Teriflunomide
 ( DHODH )		Clinically isolated syndrome
More
Phase 1
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free